Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

Amgen’s Phase 1 data shows no association between MariTide and bone mineral density changes, supporting its safety claims. Analyst highlights that study data suggests a 4% BMD decrease at the ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

If MariTide achieves 22-23% weight loss in the phase 3 trial and CagriSema and retatrutide are in the 24-27% range which I estimated based on the available phase 2 data, I do not believe that the ...

Leerink notes that Amgen’s (AMGN) Phase 2 MariTide showed "up to ~20% average weight loss at 52 weeks" in nondiabetic obese/overweight patients, which is roughly on par with the highest, 15 mg ...

If MariTide lives up to the hype, Amgen's market cap could easily double, perhaps triple on value within a couple of years. Concluding Thoughts Ahead Of Q3 Earnings ...

Salim Syed has given his Hold rating due to a combination of factors surrounding Amgen’s recent data on MariTide, a potential treatment for obesity. The efficacy results from the 52-week Phase 2 ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As ...

Calling MariTide an “important breakthrough,” Susan Sweeney, Amgen’s executive vice president obesity and related conditions, said that beyond obesity and type 2 diabetes, the drug will also ...

Amgen investors are focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, given ...